Pharmacotherapy for Patients with Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although pharmacotherapy is not the cornerstone of obesity treatment, it is a valuable tool that could be considered for patients who have not had adequate benefit from lifestyle interventions or who have difficulty maintaining initial weight loss over longer periods. CONTENT: This review focuses on the role of antiobesity drugs, the mechanisms by which the drugs work, potential pharmacological targets in the neural control of food intake and regulation of body weight, the history of antiobesity drugs, a summary of efficacy and safety data from clinical trials, and the clinical application of pharmacotherapy. Currently, 5 approved drug therapies are available in the US for long-term weight management, with only 2 of these meeting the stronger Food and Drug Administration (FDA) criteria of 5% weight loss relative to a placebo after 1 year and others receiving approval based on the categorical criterion of the proportions of patients achieving 5% weight loss. Interpretation of the results of clinical trials conducted before regulatory agency approval is limited by high dropout rates; thus, the results might not be replicable in clinical practice settings. Many patients who are suitable candidates for pharmacotherapy are not using the new drugs due to lack of insurance coverage and high out-of-pocket costs. SUMMARY: With the availability of 4 new drugs since 2012, clinicians in the US now have more tools for long-term weight management. The quality of pharmacotherapy clinical investigations needs considerable improvement. Future research should focus on examining the mediators and moderators of response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 1×
“As is the case with all nonsurgical interventions for treating obesity, some weight is regained when antiobesity drugs are continued beyond 1 year (42, 50, 69, 70, 78), resulting in a net placebo-subtracted mean weight loss of 2%–4% after 2–4 years, with liraglutide demonstrating the most efficacy and lorcaserin and n…”
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“0% with a placebo were reported among overweight/obese patients with T2D, confirming that the higher dose is more effective for weight loss (51).”
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Self-citationBray, G. A., Frühbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00271-3 · Cited by 1,036
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“It was also in 1997 that sibutramine, a serotonin and norepinephrine uptake inhibitor, was approved for long-term treatment of obesity; however, the manufacturer voluntarily withdrew the drug worldwide at the request of the US Food and Drug Administration (FDA) in 2010 when results of a long-term trial (27) in high-ri…”
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 2×
“As is the case with all nonsurgical interventions for treating obesity, some weight is regained when antiobesity drugs are continued beyond 1 year (42, 50, 69, 70, 78), resulting in a net placebo-subtracted mean weight loss of 2%–4% after 2–4 years, with liraglutide demonstrating the most efficacy and lorcaserin and n…”
The tempted brain eats: Pleasure and desire circuits in obesity and eating disorders
Berridge, K. C., Ho, C.-Y., Richard, J. M., & DiFeliceantonio, A. G. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.003 · Cited by 873
Cited by
Apolzan, J. W., Venditti, E. M., Edelstein, S. L., Knowler, W. C., Dabelea, D., Boyko, E. J., Pi-Sunyer, X., Kalyani, R. R., Franks, P. W., Srikanthan, P., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1605 · Cited by 156
Self-citationBAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control
Axelrod, C. L., King, W. T., Davuluri, G., Noland, R. C., Hall, J., Hull, M., Dantas, W. S., Zunica, E. R., Alexopoulos, S. J., Hoehn, K. L., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012088 · Cited by 89
The limits and challenges of antiobesity pharmacotherapy
Gadde, K. M., & Atkins, K. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1748599 · Cited by 65
Self-citationRocha-González, H. I., De la Cruz-Álvarez, L. E., Kammar-García, A., Canizales-Quinteros, S., Huerta-Cruz, J. C., Barranco-Garduño, L. M., & Reyes-García, J. G. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121354 · Cited by 10
“Although the efficacy of various anti-obesity drugs has been related to specific predictors such as the phentermine/topiramate, for patients who report eating disorders [8], naltrexone/bupropion, for patients who struggle with addiction [9,10], or even a cutoff of 1.”
BackgroundCabrera-Rode, E., Cubas-Dueñas, I., Acosta, J. R., Hernández, J. C., González, A. I. C., Calero, T. M. G., Domínguez, Y. A., Rodríguez, J. H., Rodríguez, A. D. R., Álvarez Álvarez, A., et al. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-03847-7 · Cited by 2
“However, despite the emergence of some promising weight-loss drugs aimed at halting the progression of prediabetes and diabetes, post-marketing surveillance has unfortunately revealed many of these medicatons to be associated with adverse events [23, 24, 27].”
Background
Metadata
- Authors
- Gadde, K. M., Apolzan, J. W., & Berthoud, H.-R.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-01
- Volume
- 64
- Issue
- 1
- Pages
- 118-129
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2766795193
- Cited by
- 57
- References
- 28
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy for Patients with Obesity. https://app.cochat.ai/papers/10.1373/clinchem.2017.272815
- The paper
- Gadde, K. M., Apolzan, J. W., & Berthoud, H.-R. (2018). Pharmacotherapy for Patients with Obesity. Clinical Chemistry. https://doi.org/10.1373/clinchem.2017.272815
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.